1. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient
- Author
-
Fernando Lombi, Deirdre Sawinski, Horacio Pereyra, Mariano Forrester, Hernán Trimarchi, Emilio Freixas, and Cristina Elizondo
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,Pamidronate ,Antineoplastic Agents ,Renal Dialysis ,Internal medicine ,medicine ,Humans ,Disodium pamidronate ,Multiple myeloma ,Kidney ,Diphosphonates ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Endocrinology ,medicine.anatomical_structure ,Nephrology ,Calcium concentration ,Hypercalcemia ,Kidney Failure, Chronic ,Bone marrow ,Hemodialysis ,Multiple Myeloma ,business - Abstract
Background A 48-year-old man with a recent diagnosis of multiple myeloma and rapidly progressive oliguric end-stage renal disease requiring hemodialysis, presented with a serum calcium concentration of 3.4 mmol/l (13.6 mg/dl). Investigations Serum laboratory analysis, electroencephalogram, MRI of the brain and bone marrow, and kidney biopsies. Diagnosis Hypercalcemia secondary to multiple myeloma. Management Short-term intravenous disodium pamidronate therapy (30 mg daily) and daily monitoring of serum calcium concentration.
- Published
- 2006